JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma /leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B cell lymphoma / leukemia.
B Acute Lymphoblastic Leukemia|B-Non Hodgkin Lymphoma
DRUG: JY231 Injection
Incidence of adverse events(AE) after infusion, The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included, Day 28、Month 2、Month 3、Month 6、Month 12、Month 18、Month 24|Maximal Tolerated Dose(MTD), MTD will be determined based on Dose-Limiting Toxicity(DLTs) observed during the first 28 days of study treatment., Up to 28 days after infusion
Objective Response Rate, Objective Response Rate(ORR) is defined as the proportion of subjects achieving complete remission(CR) and partial response(PR), Up to 3 months after infusion
This open-label, single-arm study is designed to evaluate the efficacy and safety of in vivo CAR-T cell therapy in patients with relapsed/refractory B cell lymphoma/leukaemia. Upon enrolment, leukapheresis will be performed and patients will receive 3-5 days of fludarabine and cyclophosphamide lymphodepleting therapy followed by an intravenous infusion of the JY231 preparation. Following the infusion, subjects will be evaluated for safety and efficacy for up to 24 months to determine if the disease is under control.